Company intelligence / Profile preview

Lumen Bioscience

Seattle, Washington, USAlumen.bio ↗

Ownership: Private
Employees: ~90
Development stage: Phase 2

Overview

Lead program LMN-801 for weight loss is in development, with several earlier-stage metabolic programs. LMN-201 for C. difficile infection prevention was the first rationally engineered, complex biologic cocktail to enter human clinical trials.

Therapeutic areas: GastroenterologyMetabolic DisordersInfectious Diseases
Modalities: Biologic drugstherapeutic proteinsantibodiescytokinesenzyme cocktails
Industry: Biotech

Drug pipeline

7 assets

LMN-201

6 more assets in the full pipeline.

Request access →

Partnerships

BARDACARBXThe Bill & Melinda Gates FoundationUSAMRD/MTEC

Beyond the preview

Go deeper on Lumen Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumen Bioscience.

Explore the full profile